Jump Financial’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Jump Financial’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,190	Closed	-$393K	–	1796
2023 Q3	$393K	Sell	8,190 -7,627	-48%	-$392K	0.01%	1143
2023 Q2	$823K	Buy	15,817 +4,249	+37%	+$234K	0.03%	790
2023 Q1	$627K	Buy	+11,568	New	+$653K	0.03%	789
2022 Q2	–	Sell	-8,301	Closed	-$515K	–	1623
2022 Q1	$515K	Buy	+8,301	New	+$510K	0.02%	798

Other funds holding BIB

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

CCWM

Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

CCP

Clarity Capital Partners Newport Beach, California $280M AUM 25.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jump Financial's BIB Position: Q4 2023 in Review

Jump Financial sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2023, closing a stake of 8,190 shares — an estimated $393K sold.

Jump Financial first reported a position in BIB in Q1 2022 and held it in 4 quarters. The position peaked at $823K in Q2 2023. 22 funds tracked by Wall St. Rank hold BIB as of Q4 2023.

Jump Financial reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2023 after selling out during the quarter.
Jump Financial sold 8,190 ProShares Ultra NASDAQ Biotechnology shares in Q4 2023, an estimated $393K.
Jump Financial first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2022 and held it in 4 quarters.
Jump Financial's ProShares Ultra NASDAQ Biotechnology position peaked at $823K in Q2 2023.
22 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2023.

Based on Jump Financial's 13F filing for Q4 2023, filed 7 Feb 2024.